Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA

Clinical Infectious Diseases

Volumn 31, Issue 5, 2000, Pages 1274-1278

  Raffi, François ^a   Bonnet, Bénédicte ^a   Ferré, Virginie ^a   Esnault, Jean Luc ^a   Perré, Philippe ^b   Reliquet, Véronique ^a   Leautez, Sophie ^a   Bouillant, Christine ^a   Vergnoux, Odile ^c   Weinbreck, Pierre ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier Departemental   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY COLIC; LIPODYSTROPHY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034458546     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317424     Document Type: Article

References (20)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
6. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?
7. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM)study
8. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
9. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine and indinavir in previously untreated HIV-1 infected patients
10. Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial
11. The Atlantic Study: A randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 weeks date
12. The VIRGO trial: D4T/ddI/NVP (bid or qd) in antiretroviral-naive HIV-1-infected patients: A convenient and potent regimen
13. Once-daily dosing of nevirapine: A retrospective, cross-study analysis
14. Initial HIV-1 clearance rate in antiretroviral naive patients after antiretroviral therapy with d4T plus ddI plus either NVP, IDV or 3TC (NIL)
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
16. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
17. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
18. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
19. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults
20. Transient elevation of serum HIV antigen levels associated with intercurrent infection